BI-847325 is primarily used in research settings as a potent and selective inhibitor of the Aurora kinase family, particularly Aurora A and Aurora B. These kinases play critical roles in cell division and mitotic regulation, making them targets of interest in oncology research. BI-847325 has been investigated for its antitumor activity, as it disrupts mitotic progression, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Its application extends to preclinical studies where it helps elucidate the function of Aurora kinases in tumor development and progression. Researchers use BI-847325 to evaluate the therapeutic potential of Aurora kinase inhibition in various cancer models, including solid tumors and hematological malignancies. Due to its ability to induce polyploidy and inhibit proliferation in cancer cell lines, it serves as a valuable tool compound in screening and mechanistic studies aimed at developing new anticancer therapies.